The EuMederis platform technology (EuPort) is directed at improvements in the bioavailability and duration of action of peptide therapeutics. This technology is designed to be effective for the administration of peptides by subcutaneous, intranasal and oral routes.
When used for subcutaneous administration, EuPort-modified products form a micellar/liquid crystal depot for extended release (fully flexible for pharmacodynamic profiles lasting hours to days).
Transmucosal bioavailability is facilitated by the surfactant like character of the new chemical entity achieved by linkage to the EuPort modification.
The novelty and efficacy of our proprietary modifications allows broad entry into a wide range of intellectual property space for the resultant pharmaceutical candidates. International search reports support the complete novelty of the EuPort modification and broad international patent filings are in process.
Although there are many therapeutics that slow the loss of bone, only the parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) family provides dramatic increases in bone density. Nonetheless, current use of PTH requires daily, long-term use of subcutaneous injections and may not be well-received by all patients.
EuMederis is investigating truncated analogs of PTH and PTHrP for their use as bone anabolic agents with improved bioavailability and function.
EuMederis has now shown proof of concept, both in cellular assays and in vivo, with Eu-232, a highly potent and long-acting analog of PTHrP for use with a modified route and timing of administration in osteoporosis patients.
Alleviation of pain remains one of the central challenges to physicians and many candidates have been investigated. Nonetheless, it remains an area with major unmet medical needs. Current treatment continues to rely on opiates, with their inherent side effects: respiratory depression, somnolence, tolerance, addiction potential, and constipation.
EuMederis is evaluating mu opioid receptor agonists that block pain, but which are restricted to the periphery, therefore without the potential for central side effects such as respiratory depression, drowsiness, dependence and addiction.
EuMederis has now shown proof of concept, both in cellular assays and in vivo, with Eu-178, a highly potent analog of an endogenous opioid peptide, combining full mu receptor agonism with highly potent delta receptor antagonism.
Obesity, and the resultant Metabolic Syndrome (insulin resistance, diabetes, hypertension, atherosclerosis), has become a worldwide epidemic and is responsible for one of the largest categories of healthcare costs in developed countries. Obesity results in a systemic inflammatory state that drives the downstream sequela.
EuMederis has multiple projects directed at addressing this syndrome, both from the direction of satiety induction/metabolism increase and by addressing the inflammatory cytokine response.
EuMederis Pharmaceuticals comes from the Latin and indicates our commitment to the identification of novel pharmaceuticals that represent important advances for patient health and well-being:
Eu = good, true
Mederis = to cure (future tense)
Breadth of Application
A number of additional projects are in the design and patent filing stages. If your company has an interest in peptide hormones, your project may already be in planning at EuMederis Pharmaceuticals.
Call us for a discussion of how we can help you identify superior clinical candidates.